<ul><li>A recent study presented at the ATS 2025 International Conference in San Francisco uncovered a surprising link between pharmacologically induced REM sleep suppression and increased survival rates in ALS patients.</li><li>REM sleep, crucial for cognitive and emotional functions, can pose risks for ALS patients due to muscle paralysis, leading to respiratory vulnerabilities during sleep.</li><li>Research by Dr. Cosmo Fowler from Emory University suggests that REM-suppressing antidepressants may decrease diaphragmatic paralysis, reducing respiratory complications and enhancing patient longevity.</li><li>These findings may revolutionize ALS treatment approaches towards targeting sleep architecture to improve survival rates, prompting the need for further prospective clinical trials.</li></ul>

Medications Suppressing REM Sleep Linked to Improved Survival in ALS Patients

Discover more